This Aussie medtech is taking aim at a US bladder-control stronghold featuring Australis Scientific
- Medtech giants Boston Scientific and Medtronic are doubling down on bladder-control therapies, confirming this space as one of the sector’s fastest-growing battlegrounds.
- Australis Scientific is pursuing the same therapeutic nerve pathway as those market leaders’ ankle-based implant devices, but with a simpler, wearable solution.
- Early Australian clinical data suggests its performance matches current therapies while offering a scalable, patient-friendly model.
American medtech titans Boston Scientific and Medtronic have both intensified investment in bladder-control therapies, targeting the needs of ageing populations across Western markets.
Their focus is on tibial nerve stimulation (TNS) via ankle implants. These devices connect to the neural highway that links the brain and the bladder.
For investors, the rising competition in this fast-moving field is also spotlighting Australian innovator Australis Scientific. The company is addressing the same nerve and the same multi-billion-dollar market, but with a discreet wearable patch instead of an implanted device.
